Table 5 Comparison of the results between present and earlier studies
Authors | Lee et al. [12] | Jung et al. [13] | Cho et al. [14] | Sallustio et al. [15] | Jeon et al. [16] | Oki et al. [17] | Present report |
|---|---|---|---|---|---|---|---|
Number of cases | 26 | 19 | 27 | 24 | 62 | 12 | 34 |
Age (years, mean/median) | 63 (median) | 69 (median) | 69 (mean) | 69 (mean) | 70 (median) | 64 (mean) | 64.5 (mean) |
Male, sex | 18 (69.2%) | 9 (47.4%) | 20 (74.1%) | 8 (33.3%) | 29 (46.8%) | 5 (41.7%) | 17 (50%) |
Baseline NIHSS (mean/median) | 14 (median) | 16 (median) | 11 (median) | 14.2 (mean) | 15 (median) | 17.2 (mean) | 18 (median) |
Cancer stage IV (%) | N/A | 89.5% | 29.6% | 41.7% | 69.4% | 58.0% | 64.7% |
Prestroke mRS ≤ 2 | N/A | N/A | 100.0% | 95.8% | N/A | 83.0% | 88.2% |
IV-rtPA | 19.2% | 15.8% | 63.0% | 45.8% | 14.5% | 33.0% | 26.5% |
Punture-to-reperfusion time (min, mean/median) | 59.5 (median) | 30 (median) | N/A | 52.9 (mean) | 29 (median) | 70 (mean) | 66.5 (median) |
Succesful reperfusion (mTICI 2b or 3) | 88.5% | 63.2% | 85.2% | 76.9% | 75.8% | 83.0% | 76.5% |
mRS 0–2 at 3 months | 23.1% | 15.8% | 37.0% | 41.7% | 17.7% | 25.0% | 32.0% |
Mortality at 3 months | 30.8% | 63.2% | 33.3% | 29.1% | 48.4% | 50.0% | 26.5% |
Mortality at 12 months | N/A | N/A | N/A | N/A | N/A | 92.0% | N/A |